Adenosine A2A Receptor Antagonist Istradefylline (KW-6002) Reduces "Off' Time in Parkinson's Disease : A Double-Blind, Randomized, Multicenter Clinical Trial (6002-US-005)
Identifieur interne : 002418 ( Main/Exploration ); précédent : 002417; suivant : 002419Adenosine A2A Receptor Antagonist Istradefylline (KW-6002) Reduces "Off' Time in Parkinson's Disease : A Double-Blind, Randomized, Multicenter Clinical Trial (6002-US-005)
Auteurs : Peter A. Lewitt [États-Unis] ; M. Guttman [Canada] ; James W. Tetrud [États-Unis] ; Paul J. Tuite [États-Unis] ; Akihisa Mori [Japon] ; Philip Chaikin [États-Unis] ; Neil M. Sussman [États-Unis]Source :
- Annals of neurology [ 0364-5134 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Objective: Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor antagonist, istradefylline, shows promise for the treatment of PD. Methods: Istradefylline (40mg/day) was studied in levodopa-treated PD subjects experiencing prominent wearing-off motor fluctuations. At 23 North American sites, 196 subjects were randomized in a double-blind, 12-week outpatient clinical trial of istradefylline (114 completing the trial) or placebo (58 completing the trial). The primary efficacy measure was change from baseline to end point in the percentage of daily awake "off" time, recorded by subjects using a patient PD diary. Secondary end points evaluated "on" time (including "on time with dyskinesia"), the Unified Parkinson's Disease Rating Scale, and a Clinical Global Impression-Improvement of Illness score. Clinical laboratory, electrocardiograms, vital signs, and adverse event monitoring comprised the safety monitoring. Results: After randomization, approximately 88% of subjects completed the double-blind period. Compared with baseline, the decrease of daily awake "off' time for istradefylline was a mean (± standard deviation) of -10.8 ± 16.6% (95% confidence interval, -13.46 to -7.52) and for placebo, -4.0 ± 15.7% (95% confidence interval, -7.73-0.31; p = 0.007 using two-way analysis of variance). This effect corresponded to changes from baseline in total daily awake "off' time of -1.8 ± 2.8 hours for istradefylline and -0.6 ± 2.7 hours for placebo (p = 0.005). Treatment-emergent adverse effects with istradefylline were generally mild. Interpretation: Istradefylline was safe, well tolerated, and offered a clinically meaningful reduction in "off' time without increased troublesome dyskinesia.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000661
- to stream PascalFrancis, to step Curation: 000649
- to stream PascalFrancis, to step Checkpoint: 000569
- to stream Main, to step Merge: 002630
- to stream Main, to step Curation: 002418
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Adenosine A<sub>2A</sub> Receptor Antagonist Istradefylline (KW-6002) Reduces "Off' Time in Parkinson's Disease : A Double-Blind, Randomized, Multicenter Clinical Trial (6002-US-005)</title><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Henry Ford Hospital</s1><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Department of Neurology, Henry Ford Hospital</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Wayne State University School of Medicine</s1><s2>Detroit, MI</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Detroit, MI</wicri:noRegion></affiliation></author><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Tetrud, James W" sort="Tetrud, James W" uniqKey="Tetrud J" first="James W." last="Tetrud">James W. Tetrud</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>The Parkinson Institute</s1><s2>Sunnyvale, CA</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>The Parkinson Institute</wicri:noRegion></affiliation></author><author><name sortKey="Tuite, Paul J" sort="Tuite, Paul J" uniqKey="Tuite P" first="Paul J." last="Tuite">Paul J. Tuite</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Minnesota</s1><s2>Minneapolis, MN</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Minneapolis, MN</wicri:noRegion></affiliation></author><author><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Kyowa Hakko Kogyo Co., Ltd</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Chaikin, Philip" sort="Chaikin, Philip" uniqKey="Chaikin P" first="Philip" last="Chaikin">Philip Chaikin</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Kyowa Pharmaceutical, Inc</s1><s2>Princeton, NJ</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Princeton, NJ</wicri:noRegion></affiliation></author><author><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Kyowa Pharmaceutical, Inc</s1><s2>Princeton, NJ</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Princeton, NJ</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0192208</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0192208 INIST</idno><idno type="RBID">Pascal:08-0192208</idno><idno type="wicri:Area/PascalFrancis/Corpus">000661</idno><idno type="wicri:Area/PascalFrancis/Curation">000649</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000569</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000569</idno><idno type="wicri:Area/Main/Merge">002630</idno><idno type="wicri:Area/Main/Curation">002418</idno><idno type="wicri:Area/Main/Exploration">002418</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Adenosine A<sub>2A</sub> Receptor Antagonist Istradefylline (KW-6002) Reduces "Off' Time in Parkinson's Disease : A Double-Blind, Randomized, Multicenter Clinical Trial (6002-US-005)</title><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Henry Ford Hospital</s1><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Department of Neurology, Henry Ford Hospital</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Wayne State University School of Medicine</s1><s2>Detroit, MI</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Detroit, MI</wicri:noRegion></affiliation></author><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Tetrud, James W" sort="Tetrud, James W" uniqKey="Tetrud J" first="James W." last="Tetrud">James W. Tetrud</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>The Parkinson Institute</s1><s2>Sunnyvale, CA</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>The Parkinson Institute</wicri:noRegion></affiliation></author><author><name sortKey="Tuite, Paul J" sort="Tuite, Paul J" uniqKey="Tuite P" first="Paul J." last="Tuite">Paul J. Tuite</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University of Minnesota</s1><s2>Minneapolis, MN</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Minneapolis, MN</wicri:noRegion></affiliation></author><author><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Kyowa Hakko Kogyo Co., Ltd</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>5 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Chaikin, Philip" sort="Chaikin, Philip" uniqKey="Chaikin P" first="Philip" last="Chaikin">Philip Chaikin</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Kyowa Pharmaceutical, Inc</s1><s2>Princeton, NJ</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Princeton, NJ</wicri:noRegion></affiliation></author><author><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Kyowa Pharmaceutical, Inc</s1><s2>Princeton, NJ</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Princeton, NJ</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Annals of neurology</title><title level="j" type="abbreviated">Ann. neurol.</title><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>A2A adenosine receptor</term><term>Clinical trial</term><term>Istradefylline</term><term>Multicenter study</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Récepteur adénosinique A2A</term><term>Istradéfylline</term><term>Etude multicentrique</term><term>Essai clinique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A<sub>2A</sub> receptor antagonist, istradefylline, shows promise for the treatment of PD. Methods: Istradefylline (40mg/day) was studied in levodopa-treated PD subjects experiencing prominent wearing-off motor fluctuations. At 23 North American sites, 196 subjects were randomized in a double-blind, 12-week outpatient clinical trial of istradefylline (114 completing the trial) or placebo (58 completing the trial). The primary efficacy measure was change from baseline to end point in the percentage of daily awake "off" time, recorded by subjects using a patient PD diary. Secondary end points evaluated "on" time (including "on time with dyskinesia"), the Unified Parkinson's Disease Rating Scale, and a Clinical Global Impression-Improvement of Illness score. Clinical laboratory, electrocardiograms, vital signs, and adverse event monitoring comprised the safety monitoring. Results: After randomization, approximately 88% of subjects completed the double-blind period. Compared with baseline, the decrease of daily awake "off' time for istradefylline was a mean (± standard deviation) of -10.8 ± 16.6% (95% confidence interval, -13.46 to -7.52) and for placebo, -4.0 ± 15.7% (95% confidence interval, -7.73-0.31; p = 0.007 using two-way analysis of variance). This effect corresponded to changes from baseline in total daily awake "off' time of -1.8 ± 2.8 hours for istradefylline and -0.6 ± 2.7 hours for placebo (p = 0.005). Treatment-emergent adverse effects with istradefylline were generally mild. Interpretation: Istradefylline was safe, well tolerated, and offered a clinically meaningful reduction in "off' time without increased troublesome dyskinesia.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Japon</li><li>États-Unis</li></country><region><li>Ontario</li></region><settlement><li>Tokyo</li><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="États-Unis"><noRegion><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name></noRegion><name sortKey="Chaikin, Philip" sort="Chaikin, Philip" uniqKey="Chaikin P" first="Philip" last="Chaikin">Philip Chaikin</name><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name><name sortKey="Tetrud, James W" sort="Tetrud, James W" uniqKey="Tetrud J" first="James W." last="Tetrud">James W. Tetrud</name><name sortKey="Tuite, Paul J" sort="Tuite, Paul J" uniqKey="Tuite P" first="Paul J." last="Tuite">Paul J. Tuite</name></country><country name="Canada"><region name="Ontario"><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name></region></country><country name="Japon"><noRegion><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002418 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002418 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:08-0192208
|texte= Adenosine A2A Receptor Antagonist Istradefylline (KW-6002) Reduces "Off' Time in Parkinson's Disease : A Double-Blind, Randomized, Multicenter Clinical Trial (6002-US-005)
}}
| This area was generated with Dilib version V0.6.29. |  |